Loading
A phase 3 trial of Patidegib Topical Gel in basal cell carcinoma, run by Sol-Gel Technologies, Ltd., now completed.
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome is a phase 3 interventional study registered as NCT06050122 by Sol-Gel Technologies, Ltd., with 140 participants enrolled, started 2024-03-17 and reached its primary completion in 2026-08-20. Interventions recorded: Patidegib Topical Gel and Patidegib Topical Gel with no active patidegib.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Patidegib, Patidegib gel in Gorlin syndrome (phase 2A), STEVIE (vismodegib in ordinary practice), Why people stop taking hedgehog inhibitors.